TrialPath
Recruiting

A Phase I Clinical Study of YN003 in the Treatment of Glioma

NCT07929909 · Beijing Inno Medicine Co., Ltd.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of YN003 Injection in Patients With Glioma
About this study
YN003 is an investigationalliposome injection designed to deliver the active drug preferentially to specific glioma tissue. Part A will evaluate ascending doses of YN003 administered by intravenous infusion once every 4 weeks to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). The dose-limiting toxicity (DLT) observation period is 28 days. Approximately 21 to 30 DLT-evaluable subjects will be enrolled in Part A. Part B will enroll approximately 10 to 20 additional subjects at the RP2D to further evaluate safety, pharmacokinetics, and preliminary efficacy. The study will be conducted in the United States and China.
Eligibility criteria
Inclusion Criteria: * Voluntarily sign the informed consent form, understand the study, and be willing to comply with the protocol and complete all study procedures. * Male or female subjects 18 years ≤ aged ≤ 70 years. * Histologically confirmed recurrent or progressive glioma, including glioblastoma, as defined by the 2021 WHO Classification of Tumors of the Central Nervous System, Grade 3 to Grade 4, following standard therapy.Excluding re-irradiation for same lesions * Karnofsky Performance Status (KPS) ≥60. * At least one measurable lesion per RANO 2.0 criteria. * Have adequate hematologic, cardiac, hepatic, renal, coagulation, and pulmonary function at final screening. * Have completed the required washout period for prior therapies before dosing on Day 1. * Corticosteroid dose must be stable or tapering within 7 days prior to dosing. Exclusion Criteria: * Participation in another interventional clinical study within 1 month prior to the date when subject signed the consent form. * Receipt of a live vaccine within 30 days prior to study treatment. * Pregnant or breastfeeding women. * Clinically significant intracranial hypertension (e.g., impending brain herniation or requiring urgent palliative intervention) or uncontrolled seizures. Subjects requiring antiepileptic drugs are eligible only if the dose has been stable for ≥ 14 days prior to first dosing * Toxicities from prior anticancer therapy that have not recovered to CTCAE v6.0 Grade ≤1, except for alopecia or other events considered tolerable by the investigator. * Contraindications to MRI, including but not limited to pacemakers, epicardial pacing leads, infusion pumps, aneurysm clips, metal fragments, metallic prostheses, magnetic implants, intraocular metal objects, or non-removable metallic dental implants. * Uncontrolled or severe cardiovascular or cerebrovascular disease
Study design
Enrollment target: 50 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-10-27
Estimated completion: 2029-12-31
Last updated: 2026-11-10
Interventions
Drug: YN003 Injection
Primary outcomes
  • • To Incidence and characteristics of AEs/SAEs; (From first dose of YN003 to 30 days after the last dose (or initiation of new antitumor therapy, whichever occurs first))
  • • Incidence of clinically significant abnormalities in laboratory tests (From first dose of YN003 to 30 days after the last dose (or initiation of new antitumor therapy, whichever occurs first))
  • • Incidence of clinically significant abnormalities in vital signs (From first dose of YN003 to 30 days after the last dose (or initiation of new antitumor therapy, whichever occurs first))
Sponsor
Beijing Inno Medicine Co., Ltd. · industry
Contacts & investigators
ContactKaiqi Zong, Master · contact · zongkaiqi@innovmedicine.com · 13683178623
ContactYaqian Cui, Master · contact · cuiyaqian@innovmedicine.com · 18811320289
All locations (5)
University of California, Los Angeles (UCLA)Not Yet Recruiting
Los Angeles, California, United States
University of California, San Francisco (UCSF)Not Yet Recruiting
San Francisco, California, United States
The University of Texas MD Anderson Cancer CenterNot Yet Recruiting
Houston, Texas, United States
Beijing Tsinghua Changgung HospitalRecruiting
Beijing, Beijing Municipality, China
Sanbo Brain Hospital, Capital Medical UniversityRecruiting
Beijing, Beijing Municipality, China
A Phase I Clinical Study of YN003 in the Treatment of Glioma · TrialPath